EGFR and non-small cell lung carcinoma: Moreover, a prospective, three-arm study investigating the combination of anlotinib with either EGFR-TKI, chemotherapy, or immune checkpoint inhibitors (ICIs) demonstrated notable tolerability and promising efficacy as first-line therapies in NSCLC patients (34).